News

Respiratory syncytial virus (RSV) infections were associated with significantly increased risk for complications beyond ...
With the 2025 influenza season starting earlier than usual, the NICD urges South Africans to stay vigilant against seasonal ...
The votes on vaccine recommendations are the first move by the panel after Health and Human Services Secretary Robert F.
Understanding the differences between colds, flu, and RSV can help in identifying the illness you're dealing with, the ...
Hospital readmission risk in pediatric patients was higher in those who were first admitted for RSV than in those who were first admitted for influenza or hMPV.
The ACIP is recommending the use of Enflonsia for the prevention of RSV lower respiratory tract disease in infants younger than 8 months.
Merck & Co., Inc. (NYSE: MRK) is one of the. The company announced that the US FDA approved ENFLONSIA™ (clesrovimab-cfor) for ...
The eight new ACIP members met for the first time June 25 after Kennedy fired all 17 original members of the committee June 9 ...
Respiratory syncytial virus is common but it can be dangerous for some infants and young kids. Here's everything parents need ...
The recommendation for Enflonsia is indicated for respiratory syncytial virus prevention in infants under eight months of age ...
RAHWAY, N.J., June 26, 2025--ACIP Recommends Merck’s ENFLONSIA for Prevention of RSV in Infants Younger than 8 Months of Age Born During or Entering Their First RSV Season ...
Merck's Enflonsia vaccine for respiratory syncytial virus won approval from the Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices.